秋水仙碱联合氨苯砜治疗对秋水仙碱耐药的家族性地中海热患者
Colchicine plus Dapsone in Colchicine-Resistant FMF Patients.
作者信息
Salehzadeh Farhad, Enteshary A, Moshkbar M
机构信息
Professor in Pediatric Rheumatology, Pediatric Department, Bouali Children's Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran.
Assistant Professor of Rheumatology, Internal Medicine Department, Imam Khomeini Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran.
出版信息
Case Rep Rheumatol. 2019 Jan 9;2019:2716127. doi: 10.1155/2019/2716127. eCollection 2019.
Abstract
Five to ten percent of FMF patients have unfavorable response to the colchicine as a standard therapy. Biologic treatments have been shown to be highly effective, but there are often unavailable, because the price is unaffordably high. This study shows the striking effect of combined dapsone and colchicine therapy in such patients and recommends it as an alternative therapy in colchicine-resistant (CR) patients.
摘要
5%至10%的家族性地中海热（FMF）患者对作为标准疗法的秋水仙碱反应不佳。生物治疗已被证明非常有效，但往往无法获得，因为价格高得令人难以承受。这项研究显示了氨苯砜和秋水仙碱联合治疗在此类患者中的显著效果，并推荐将其作为秋水仙碱耐药（CR）患者的替代疗法。
相似文献
1
Colchicine plus Dapsone in Colchicine-Resistant FMF Patients.秋水仙碱联合氨苯砜治疗对秋水仙碱耐药的家族性地中海热患者
Case Rep Rheumatol. 2019 Jan 9;2019:2716127. doi: 10.1155/2019/2716127. eCollection 2019.
2
Association between colchicine resistance and vitamin D in familial Mediterranean fever.家族性地中海热中秋水仙碱耐药性与维生素D之间的关联。
Ren Fail. 2015 Aug;37(7):1122-5. doi: 10.3109/0886022X.2015.1056064. Epub 2015 Jun 12.
3
Efficacy and safety of biologic treatments in Familial Mediterranean Fever.生物制剂治疗家族性地中海热的疗效和安全性。
Am J Med Sci. 2013 Aug;346(2):137-41. doi: 10.1097/MAJ.0b013e318277083b.
4
Biologic therapy in familial Mediterranean fever.家族性地中海热的生物治疗
Mod Rheumatol. 2016 Sep;26(5):637-41. doi: 10.3109/14397595.2016.1162261. Epub 2016 Apr 21.
5
Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine.对于对秋水仙碱无反应的患者，用卡那单抗治疗家族性地中海热。
Eur J Rheumatol. 2019 Apr 1;6(2):85-88. doi: 10.5152/eurjrheum.2019.18190. Print 2019 Apr.
6
Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.托珠单抗用于对秋水仙碱耐药或不耐受的家族性地中海热的疗效和安全性比较：一项研究者发起的、多中心、随机、双盲、安慰剂对照试验的研究方案
Trials. 2018 Dec 29;19(1):715. doi: 10.1186/s13063-018-3105-6.
7
Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare.用于治疗家族性地中海热的秋水仙碱、生物制剂及其他药物。旧药、新药与罕见药
Curr Med Chem. 2016;23(1):60-86. doi: 10.2174/0929867323666151117121706.
8
Successful treatment of complex aphthosis with colchicine and dapsone.秋水仙碱和氨苯砜成功治疗复杂性口疮性口炎。
Arch Dermatol. 2009 Mar;145(3):273-6. doi: 10.1001/archdermatol.2008.591.
9
Familial Mediterranean fever in childhood: a single-center experience.儿童期家族性地中海热：单中心经验。
Rheumatol Int. 2018 Jan;38(1):67-74. doi: 10.1007/s00296-017-3796-0. Epub 2017 Aug 21.
10
Efficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine.静脉秋水仙碱长期治疗对口服秋水仙碱治疗无效的家族性地中海热（FMF）的疗效和安全性。
Rheumatol Int. 2019 Mar;39(3):517-523. doi: 10.1007/s00296-018-04237-w. Epub 2019 Jan 2.
本文引用的文献
1
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.卡那奴单抗治疗自身炎症性反复发作性发热综合征。
N Engl J Med. 2018 May 17;378(20):1908-1919. doi: 10.1056/NEJMoa1706314.
2
Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS.自身炎症性疾病家族性地中海热（FMF）和高免疫球蛋白D综合征（HIDS）中的吡啉炎性小体激活和RhoA信号传导
Nat Immunol. 2016 Aug;17(8):914-21. doi: 10.1038/ni.3457. Epub 2016 Jun 6.
3
Biologic therapy in familial Mediterranean fever.家族性地中海热的生物治疗
Mod Rheumatol. 2016 Sep;26(5):637-41. doi: 10.3109/14397595.2016.1162261. Epub 2016 Apr 21.
4
Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare.用于治疗家族性地中海热的秋水仙碱、生物制剂及其他药物。旧药、新药与罕见药
Curr Med Chem. 2016;23(1):60-86. doi: 10.2174/0929867323666151117121706.
5
Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.利那洛肽治疗对秋水仙碱耐药或不耐受的家族性地中海热：一项随机试验。
Ann Intern Med. 2012 Oct 16;157(8):533-41. doi: 10.7326/0003-4819-157-8-201210160-00003.
6
Dapsone as an alternative therapy in children with familial mediterranean Fever.氨苯砜作为家族性地中海热患儿的替代疗法。
Iran J Pediatr. 2012 Mar;22(1):23-7.
7
Canakinumab induces remission in a patient with resistant familial Mediterranean fever.卡那单抗可诱导一名难治性家族性地中海热患者缓解。
Rheumatology (Oxford). 2012 Jun;51(6):1041. doi: 10.1093/rheumatology/kes021. Epub 2012 Mar 7.
8
The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis.卡那单抗治疗一名家族性地中海热和长期破坏性关节炎患者的疗效。
Ann Rheum Dis. 2011 Jul;70(7):1347-8. doi: 10.1136/ard.2010.146878. Epub 2011 Feb 22.
9
The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.人抗白细胞介素-1β单克隆抗体ACZ885在小鼠关节炎症模型以及类风湿关节炎患者的概念验证研究中均有效。
Arthritis Res Ther. 2008;10(3):R67. doi: 10.1186/ar2438. Epub 2008 Jun 5.
10
Familial Mediterranean fever: clinical, molecular and management advancements.家族性地中海热：临床、分子及管理方面的进展
Neth J Med. 2007 Oct;65(9):318-24.
Zotero 插件